These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 27116384)

  • 1. Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy.
    Wu W; Lin Y; Xiang L; Dong W; Hua X; Ling Y; Li H; Yan F; Xie X; Gu W
    Ann Hematol; 2016 Jun; 95(7):1051-7. PubMed ID: 27116384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.
    Lübbert M; Rüter BH; Claus R; Schmoor C; Schmid M; Germing U; Kuendgen A; Rethwisch V; Ganser A; Platzbecker U; Galm O; Brugger W; Heil G; Hackanson B; Deschler B; Döhner K; Hagemeijer A; Wijermans PW; Döhner H
    Haematologica; 2012 Mar; 97(3):393-401. PubMed ID: 22058219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
    Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
    Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decitabine and all-trans retinoic acid synergistically exhibit cytotoxicity against elderly AML patients via miR-34a/MYCN axis.
    Cao Y; Liu Y; Shang L; Wei W; Shen Y; Gu Q; Xie X; Dong W; Lin Y; Yue Y; Wang F; Gu W
    Biomed Pharmacother; 2020 May; 125():109878. PubMed ID: 32006898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
    Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy.
    Grishina O; Schmoor C; Döhner K; Hackanson B; Lubrich B; May AM; Cieslik C; Müller MJ; Lübbert M
    BMC Cancer; 2015 May; 15():430. PubMed ID: 26008690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome.
    Jeong SH; Kim YJ; Lee JH; Kim YK; Kim SJ; Park SK; Do YR; Kim I; Mun YC; Kim HG; Lee WS; Yi HG; Joo YD; Choi CW; Kim SR; Na SM; Jang JH
    Oncotarget; 2015 Dec; 6(42):44985-94. PubMed ID: 26517692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The clinical safety and efficacy of low dose subcutaneous decitabine in treating acute myeloid leukemia and intermediate- or higer-risk myelodysplastic syndromes in the elderly patients].
    Ai H; Wei XD; Yin QS; Wang P; Mi RH; Yuan FF; Chen L; Song YP
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):606-609. PubMed ID: 28789495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
    Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
    J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
    Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
    Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.
    Garcia-Manero G; Jabbour E; Borthakur G; Faderl S; Estrov Z; Yang H; Maddipoti S; Godley LA; Gabrail N; Berdeja JG; Nadeem A; Kassalow L; Kantarjian H
    J Clin Oncol; 2013 Jul; 31(20):2548-53. PubMed ID: 23733767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Daver N; Kantarjian H; Garcia-Manero G; Jabbour E; Borthakur G; Brandt M; Pierce S; Vaughan K; Ning J; Nogueras González GM; Patel K; Jorgensen J; Pemmaraju N; Kadia T; Konopleva M; Andreeff M; DiNardo C; Cortes J; Ward R; Craig A; Ravandi F
    Haematologica; 2017 Oct; 102(10):1709-1717. PubMed ID: 28729302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Daver N; Kantarjian H; Ravandi F; Estey E; Wang X; Garcia-Manero G; Jabbour E; Konopleva M; O'Brien S; Verstovsek S; Kadia T; Dinardo C; Pierce S; Huang X; Pemmaraju N; Diaz-Pines-Mateo M; Cortes J; Borthakur G
    Leukemia; 2016 Feb; 30(2):268-73. PubMed ID: 26365212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
    Ye XN; Zhou XP; Wei JY; Xu GX; Li Y; Mao LP; Huang J; Ren YL; Mei C; Wang JH; Lou YJ; Ma LY; Yu WJ; Ye L; Xie LL; Luo YW; Hu C; Niu LM; Dou MH; Jin J; Tong HY
    Leuk Lymphoma; 2016; 57(6):1311-8. PubMed ID: 26372888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
    Cashen AF; Schiller GJ; O'Donnell MR; DiPersio JF
    J Clin Oncol; 2010 Feb; 28(4):556-61. PubMed ID: 20026803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
    Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
    Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.
    Lübbert M; Grishina O; Schmoor C; Schlenk RF; Jost E; Crysandt M; Heuser M; Thol F; Salih HR; Schittenhelm MM; Germing U; Kuendgen A; Götze KS; Lindemann HW; Müller-Tidow C; Heil G; Scholl S; Bug G; Schwaenen C; Giagounidis A; Neubauer A; Krauter J; Brugger W; De Wit M; Wäsch R; Becker H; May AM; Duyster J; Döhner K; Ganser A; Hackanson B; Döhner H;
    J Clin Oncol; 2020 Jan; 38(3):257-270. PubMed ID: 31794324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia.
    Ritchie EK; Feldman EJ; Christos PJ; Rohan SD; Lagassa CB; Ippoliti C; Scandura JM; Carlson K; Roboz GJ
    Leuk Lymphoma; 2013 Sep; 54(9):2003-7. PubMed ID: 23270581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
    Blum W; Klisovic RB; Hackanson B; Liu Z; Liu S; Devine H; Vukosavljevic T; Huynh L; Lozanski G; Kefauver C; Plass C; Devine SM; Heerema NA; Murgo A; Chan KK; Grever MR; Byrd JC; Marcucci G
    J Clin Oncol; 2007 Sep; 25(25):3884-91. PubMed ID: 17679729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.
    Bhatnagar B; Duong VH; Gourdin TS; Tidwell ML; Chen C; Ning Y; Emadi A; Sausville EA; Baer MR
    Leuk Lymphoma; 2014 Jul; 55(7):1533-7. PubMed ID: 24144313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.